[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369452-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-369452-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","prevalence-and-risk-factors-for-cancer-related-fatigue-in-women-with-malignant-gynecological-tumors-a-meta-analysis-and-systematic-review","Prevalence and risk factors for cancer-related fatigue in women with malignant gynecological tumors - a meta-analysis and systematic review","","Cancer-related fatigue remains common but reported prevalence and risk factors vary across studies. This systematic review and meta-analysis aims to determine prevalence and identify associated risk factors for cancer-related fatigue in women with malignant gynecological tumors. A comprehensive database search (to September 7, 2023) evaluated eligible studies using independent review, data extraction, Newcastle-Ottawa quality assessment, and AHRQ risk-of-bias tools. Stata 17.0 supported the traditional meta-analysis, estimating overall and subgroup prevalence.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prevalence-and-risk-factors-for-cancer-related-fatigue-in-women-with-malignant-gynecological-tumors-a-meta-analysis-and-systematic-review/369452/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prevalence-and-risk-factors-for-cancer-related-fatigue-in-women-with-malignant-gynecological-tumors-a-meta-analysis-and-systematic-review/369452.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the review?","Question",{"text":63,"@type":64},"To identify the prevalence and risk factors for cancer-related fatigue in women with malignant gynecological tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which studies and databases were used in the meta-analysis?",{"text":68,"@type":64},"The review searched Web of Science, Cochrane Library, PubMed, Embase, CNKI, VIP, Wan Fang, and CBM for studies published from database inception through September 7, 2023.",{"name":70,"@type":61,"acceptedAnswer":71},"What prevalence estimates were reported for cancer-related fatigue?",{"text":72,"@type":64},"The combined prevalence of cancer-related fatigue was 89% (95% CI: 80–95%), and the combined prevalence of chronic cancer-related fatigue was 25% (95% CI: 22–28%).",{"name":74,"@type":61,"acceptedAnswer":75},"Which factors were associated with cancer-related fatigue?",{"text":76,"@type":64},"Age, psychological factors, and disease stage were associated with higher risk, while social support was protective.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},369452,1790303932,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Zhao et al. BMC Cancer (2025) 25:827 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-14210-z](https://doi.org/10.1186/s12885-025-14210-z)  \nSYSTEMATIC REVIEW Open Access  \nPrevalence and risk factors for cancerrelated fatigue in women with malignant gynecological tumors: a meta-analysis and systematic review  \nJie Zhao 1†, Liuyan Zhan 1†, Yuanyuan Pang 1, Shujie Shen 1, Jie Huang 1, Wenjia Zhang 1 and Siqi Wei 1*  \nAbstract  \nBackground Cancer-related fatigue (CRF) is one of the most prevalent symptoms, but its prevalence and associated risk factors remain inconsistent across studies.  \nObjective To identify the prevalence and risk factors for CRF in women with malignant gynecological tumors. Methods A comprehensive search of databases, including Web of Science, Cochrane Library, PubMed, Embase, CNKI, VIP, Wan Fang, and CBM, was conducted for relevant studies published from the inception of the database until September 7, 2023. Two reviewers used EndnoteX9 software to independently review, extract data, cross-check, and use the Newcastle-Ottawa quality assessment scale and the Agency for Healthcare Research and Quality tool for risk of bias assessment to evaluate bias risk. Stata 17.0 software was used to perform a traditional meta-analysis.  \nResults The meta-analysis included 33 studies, of which 29 reported the prevalence of CRF. The combined prevalence of CRF was 89%(95% confidence interval [CI]: 80–95%), and the combined prevalence of chronic CRF was 25%(95%CI: 22–28%) . The combined prevalence of CRF in patients with ovarian cancer, cervical cancer, endometrial, and gynecological malignancies (including but not limited to cervical, ovarian, vaginal and other mixed types of gynecological cancers) was 77%, 94%, 90%, and 93%, respectively. The variability in CRF measurement is due to the different scales used across studies. Its prevalence varies by country, and developing countries, especially China, have a high prevalence of CRF. The following risk factors were associated with CRF: age (odds ratio [OR] = 1 .43, 95%CI = 1.12– 1. 83), psychological factors (OR = 1 .40, 95%CI = 1 .14–1. 72), disease stage (OR = 1 . 65, 95%CI 1.14–2.40), and social support (OR = 0 . 77, 95%CI 0.67–0. 87) .  \nConclusion The prevalence of CRF is significant in women with gynecological cancers, especially in developing countries. Age, psychological factors, and disease stage are risk factors for CRF, while social support serves as a  \n†Jie Zhao and Liuyan Zhan contributed equally to this work and share first authorship.  \n*Correspondence: Siqi Wei [weisq@lzu.edu.cn](weisq@lzu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nZhao et al. BMC Cancer (2025) 25:827 Page 2 of 14  \nprotective factor. Healthcare professionals can obtain a clearer picture of CRF in women with gynecological malignant tumors and identify risk factors to support subsequent inte","cbCaioaWXnRjiK1U","https://ap.wps.com/l/cbCaioaWXnRjiK1U","pdf",1866566,14,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Epidemiology and clinical burden","[{\"question\":\"What is the main purpose of the review?\",\"answer\":\"To identify the prevalence and risk factors for cancer-related fatigue in women with malignant gynecological tumors.\"},{\"question\":\"Which studies and databases were used in the meta-analysis?\",\"answer\":\"The review searched Web of Science, Cochrane Library, PubMed, Embase, CNKI, VIP, Wan Fang, and CBM for studies published from database inception through September 7, 2023.\"},{\"question\":\"What prevalence estimates were reported for cancer-related fatigue?\",\"answer\":\"The combined prevalence of cancer-related fatigue was 89% (95% CI: 80–95%), and the combined prevalence of chronic cancer-related fatigue was 25% (95% CI: 22–28%).\"},{\"question\":\"Which factors were associated with cancer-related fatigue?\",\"answer\":\"Age, psychological factors, and disease stage were associated with higher risk, while social support was protective.\"}]","Prevalence and risk factors for cancer-related fatigue in women with malignant gynecological tumors - a meta-analysis and systematic review | PDF",1790182757,35,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9f2c655df82225fdc193ac0cdec62af.webp",983,1310,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aef456ff3dc27460c78543331b059a48.webp",982,1309,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b30fdabdc1f1e7d9db8432a401fa3b4.webp",981,1308,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6c9853dcd0b3b01ac09b15740b317ac.webp",980,1306]